Zacks Research Has Strong Estimate for IRWD FY2026 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Zacks Research increased their FY2026 EPS estimates for Ironwood Pharmaceuticals in a note issued to investors on Wednesday, January 8th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $0.44 per share for the year, up from their prior forecast of $0.43. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Separately, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.40.

Ironwood Pharmaceuticals Trading Down 3.2 %

Shares of IRWD stock opened at $3.65 on Monday. The company’s fifty day moving average price is $4.03 and its 200-day moving average price is $4.69. The stock has a market cap of $584.10 million, a PE ratio of -121.67 and a beta of 0.34. Ironwood Pharmaceuticals has a 12 month low of $3.06 and a 12 month high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The firm had revenue of $91.60 million during the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.12 EPS.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors have recently made changes to their positions in IRWD. Rhumbline Advisers lifted its position in Ironwood Pharmaceuticals by 0.7% during the second quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock valued at $2,384,000 after purchasing an additional 2,577 shares during the period. Victory Capital Management Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 74.3% in the 2nd quarter. Victory Capital Management Inc. now owns 222,573 shares of the biotechnology company’s stock worth $1,451,000 after buying an additional 94,882 shares during the last quarter. Choreo LLC bought a new stake in shares of Ironwood Pharmaceuticals in the second quarter worth $292,000. Daiwa Securities Group Inc. increased its position in Ironwood Pharmaceuticals by 9.6% during the second quarter. Daiwa Securities Group Inc. now owns 55,770 shares of the biotechnology company’s stock valued at $364,000 after acquiring an additional 4,900 shares during the last quarter. Finally, Headlands Technologies LLC lifted its holdings in Ironwood Pharmaceuticals by 127.7% in the second quarter. Headlands Technologies LLC now owns 28,657 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 16,072 shares during the period.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.